Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis

British Journal of Dermatology

Volumn 168, Issue 4, 2013, Pages 825-836

  Dirschka, T ^a,b   Radny, P ^c   Dominicus, R ^c   Mensing, H ^d   Bruning H ^e   Jenne, L ^f   Karl, L ^c   Sebastian, M ^c   Oster Schmidt, C ^g   Klovekorn W ^c   Reinhold, U ^h   Tanner, M ⁱ   Grone D ^c   Deichmann, M ^c   Simon, M ^j   Hubinger F ^c   Hofbauer, G ^k   Krahn Senftleben G ^l   Borrosch, F ^m   Reich, K ⁿ   Berking, C ^o   Wolf, P ^p   Lehmann, P ^q   Moers Carpi, M ^r   Honigsmann H ^s   Wernicke Panten, K ^t   Hahn, S ^t   Pabst, G ^u   Voss, D ^u   Foguet, M ^v   Schmitz, B ^v   Lubbert H ^v   Szeimies, R M ^w   more..

^a Private Dermatological Practice Centre   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c Dermatological Ambulatory ^*

^d Sellspeicher   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Medical Centre Bonn   (Germany)

^g University Hospital Zurich   (Germany)

^h Medical Centre Bonn   (Germany)

ⁱ SCIderm GmbH   (Germany)

^j HELIOS Hospital Wuppertal   (Germany)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l SANA KLINIKUM OFFENBACH   (Germany)

^m Focus Clinical Drug Development GmbH   (Germany)

ⁿ SCIderm GmbH   (Germany)

^o UNIVERSITY OF MUNICH   (Germany)

^p MEDICAL UNIVERSITY OF GRAZ   (Austria)

^q HELIOS KLINIKUM WUPPERTAL   (Germany)

^r Private Practice for Skin Diseases Operative and Aesthetic Dermatology   (Germany)

^s University Hospital for Dermatology   (Austria)

^t ACCOVION GMBH   (Germany)

^u FOCUS Clinical Drug Development GmbH   (Germany)

^v Biofrontera Pharmaceuticals GmbH   (Germany)

^w Klinikum Vest   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; PLACEBO;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SKIN CANCER; SKIN DEFECT; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATOSIS, ACTINIC; LONG-TERM CARE; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84875428696     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12158     Document Type: Article

References (14)

1. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56: 125-43.
2. Rowert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156 (Suppl. 3): 8-12.
3. Frost CA, Green AC, Williams GM,. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998; 139: 1033-9.
4. Frost CA, Green AC,. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455-64.
5. Maisch T, Santarelli F, Schreml S, et al. Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Exp Dermatol 2010; 19: e302-5.
6. Szeimies RM, Radny P, Sebastian M, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163: 386-94.
7. Dirschka T, Radny P, Dominicus R, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166: 137-46.
8. Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738-43.
9. Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow-up. Br J Dermatol 2006; 155: 1262-9.
10. Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009; 160: 1066-74.
11. Szeimies RM, Stockfleth E, Popp G, et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 2010; 162: 410-14.
12. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-19.
13. Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651-9.
14. Braathen LR, Paredes BE, Saksela O, et al. Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol 2008; 23: 550-5.